FDA Approves Etcamah for ctDNA-Guided Switching

FDA Action September 4, 2026 · Discovery September 4, 2026 · Status Same-day regulatory signal · Importance 5/5 · Direction Positive Summary FDA granted accelerated approval to Etcamah (camizestrant) with continued CDK4/6 inhibition for adults with HR-positive, HER2-negative advanced breast cancer whose tumors develop an…